Nopadol Soparattanapaisarn

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i> -Mutated NSCLC

Shun Lu, Terufumi Kato, Xiaorong Dong et al. · New England Journal of Medicine · 2024 · 295 citations

Medicine, Oncology, Pharmacology +15

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Michael Boyer, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu et al. · Journal of Clinical Oncology · 2021 · 253 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

Anthony T.�C. Chan, V.H.F. Lee, R-L. Hong et al. · Annals of Oncology · 2022 · 107 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin–cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study

Lucksamon Thamlikitkul, Vichien Srimuninnimit, Charuwan Akewanlop et al. · Supportive Care in Cancer · 2016 · 63 citations

Medicine, Oncology, Pharmacology +17